$AGIO News

Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52

Truist Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $39

HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $55

Agios Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Agios Pharmaceuticals, Inc. (AGIO) Q2 2026 Earnings Call Transcript

Agios Pharmaceuticals (NASDAQ:AGIO) Surges on Q2 Revenue Beat Driven by PYRUKYND Sales

Agios Pharmaceuticals Q2 EPS $(1.69) Misses $(1.67) Estimate, Sales $44.745M Beat $25.521M Estimate

Agios Reports Neutral Sickle Cell Data, Decides To Stop Development

HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $52

Agios Pharma Announces Topline Results From Phase 2 Trial Of Tebapivat, Oral Pyruvate Kinase Activator, In Patients Aged 16 Years Or Older With Sickle Cell Disease

Why Is Agios Pharma Stock Soaring Tuesday?

RBC Capital Maintains Sector Perform on Agios Pharmaceuticals, Raises Price Target to $32

Truist Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $41

Agios Pharma Says FDA Accepts sNDA For Mitapivat In Sickle Cell Disease With Priority Review; PDUFA Goal Date November 1

B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $46

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

AGIO Stock Surges 35% in Six Months: What's Driving It?

Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event - Slideshow

Reported Saturday, Agios Presents RISE UP Phase 3 Data At EHA 2026 Showing Mitapivat Achieves 40.6% Hemoglobin Response Rate And 41.1% Reduction In Transfusion Burden Versus Placebo In Sickle Cell Disease

Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss